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BACKGROUND. Prostate cancer inmen has a highmortality andmorbidity due tometastatic
disease. Thepathobiology of prostate cancermetastasis is notwell understood and cell lines and
animal models that recapitulate the complex nature of the disease are needed. Therefore, the
goal of the studywas to establish and characterize a newprostate cancer line derived fromadog
with spontaneous prostate cancer.
METHODS. A new cell line (Leo) was derived from a dog with spontaneous prostate cancer.
Immunohistochemistry and PCR were used to characterize the primary prostate cancer and
xenografts in nude mice. Subcutaneous tumor growth and metastases in nude mice were
evaluated by bioluminescent imaging, radiography and histopathology. In vitro chemosensi-
tivity of Leo cells to therapeutic agents was measured.
RESULTS. Leo cells expressed the secretory epithelial cytokeratins (CK)8, 18, and ductal cell
marker, CK7. The cell line grew in vitro (over 75 passages) andwas tumorigenic in the subcutis
of nude mice. Following intracardiac injection, Leo cells metastasized to the brain, spinal cord,
bone, and adrenal gland. The incidence ofmetastaseswas greatest to the central nervous system
(80%) with a lower incidence to bone (20%) and the adrenal glands (16%). In vitro chemo-
sensitivity assays demonstrated that Leo cells were sensitive to Velcade and an HDAC-42
inhibitor with IC50 concentrations of 1.9 nm and 0.95 mm, respectively.
CONCLUSION. The newprostate cancer cell line (Leo)will be a valuablemodel to investigate
the mechanisms of the brain and bone metastases. Prostate 71: 1251–1263, 2011.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed
cancer in men accounting for 25% of all cancers in
the United States [1]. Prostate cancer in advanced
stages has a high incidence of bone metastases that
causes severe skeletal complications resulting in mor-
bidity and mortality. Dogs are the only non-human
mammals that develop spontaneous prostate cancer,
which shares many characteristics in clinical presen-
tation and pathogenesis of the disease as in men [2]. In
addition, dogs also have extensive genomic homology
with humans, and recent sequencing of the dog
genome and development of dog gene arrays make
the dog an invaluable animal model to study the
pathogenesis of prostate cancer in spontaneous or
experimental settings [3]. Previously, our laboratory
established the ACE-1 canine prostate cancer cell line
that metastasizes almost exclusively to bone and indu-
ces mixed osteoblastic and osteolytic lesions in nude
mice similar to bone metastases in men with prostate
cancer [4].
Although bone is the primary site of metastases in
prostate cancer, metastases also occur in lymph nodes,
brain, lung, adrenal gland, and liver [5–7]. Soft tissue
metastases, alone or in combination with bone meta-
stases, were detected in 33% of prostate cancer patients
with metastases [8]. Brain metastases occurs in a small
percentage of patients (1%), but is often a terminal
event. Median survival rate is 1 month in untreated
patients with brain metastases, 3.5 months in patients
who received radiotherapy and 9 months in patients
who had stereotactic radiosurgery [9]. Although brain
metastases are uncommon in prostate cancer, the
annual incidence of more than 150,000 cases of brain
metastases from other cancers was reported in the US
[10]. It is important to develop new therapies for
patients with brain metastases due to their serious con-
sequences. Therefore, understanding the molecular
pathogenesis of prostate cancer brain metastases
will facilitate the development of novel treatment
strategies.
Although numerous prostate cancer cell lines have
been developed, few cell lines develop bone meta-
stases and no cell lines have been reported to cause
brain metastases [11]. Despite the fact that the
DU145 cell line was developed from a brain meta-
stasis from a human prostate cancer patient, these
cells have not demonstrated the ability to metastasize
to the brain in animal models [12]. Therefore, lack of
prostate cancer cell lines that develop brain metastases
have impeded studies of prostate cancer brain
metastases.
In this investigation,we report the establishment of a
novel dog prostate cancer cell line and its ability to
metastasize to numerous sites in the nude mouse




Tissue from a spontaneously arising prostate carci-
noma was collected immediately following euthanasia
of a tumor-bearing, 5-year-old, castrated male mixed
breed dog and washed three times in DMEM/F12
(Invitrogen Corp., Carlsbad, CA) containing 50 mg/
ml primocin (Invivogen, San Diego, CA) and minced
into approximately 1 mm3 pieces. The tissue pieces
were digested in 500 units/ml of collagenase type 1
(Worthington Biochemical, Lakewood, NJ) in serum-
free DMEM/F12 for 2 hr at 378C on a rocker platform
with gentle rocking. The digested tissue was washed
three timeswith DMEM/F12 containing 50 mg/ml Pri-
mocin and 10% fetal bovine serum (FBS) (Invitrogen
Corp.) and plated in a T-75 flask (Falcon; Becton-Dick-
inson, Franklin Lakes,NJ).Mediumwas changed every
3 days. Differential trypsinization was performed to
eliminate the stromal cell contamination of epithelial
cells once every 2 days by treating the cultures with
0.05% trypsin ethylenediamine-tetraacetic acid (EDTA)
(Invitrogen Corp.). Detachment of the cells was moni-
tored every 2 min to remove the stromal cells, which
detached earlier than the epithelial cells. The first phase
of detached cells (mostly stromal cells) was removed





YFP-Luc lentiviral particles were produced by tran-
sient co-transfection of 293T cellswith 10 mgpackaging
plasmid pCMVDR8.2, 2 mg envelope plasmid pMD.G
and 10 mg transfer plasmid pHIVSIN-YFP-Luc using
calcium phosphate (Sigma–Aldrich Co., St. Louis, MO)
as described previously [13]. The virus supernatant
was collected at 24 hr, filtered through a 0.2 mm filter,
and stored at 808C until use. Leo cells were trans-
duced with the retroviral YFP-Luc dual reporter gene
and 8 mg/ml polybrene by spin inoculation at
2700 rpm for 1 hr at 328C and transferred to a cell
culture incubator overnight. Cells were maintained
in DMEM/F12 medium containing 10% FBS and
50 mg/ml Normocin (Invivogen).
Subcutaneousandintracardiac left ventricular
inoculationof Leocellsinnudemice
Subcutaneous (N ¼ 10) and intracardiac (N ¼ 25)
injections of Leo YFP-Luc cells were performed in
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6-week-old male nu/nu mice (National Cancer Insti-
tute, Frederick, MD) under general anesthesia with a
3% isoflurane (Abbott Laboratories, North Chicago,
IL)-oxygen mixture. All the animal experimental pro-
cedures were approved by The Ohio State University
Institutional Laboratory Animal Care and Use Com-
mittee. Ten million Leo cells suspended in 250 ml of
phosphate-buffered saline (PBS) (Invitrogen) were
injected subcutaneously over the dorsal interscapular
area of mice. Subcutaneous tumor growth in mice was
measured weekly using Vernier calipers and biolumi-
nescent imaging (BLI) and sacrificed after 6 weeks. Left
ventricular cardiac injections were performed with
1  105 cells suspended in 100 ml of PBS using a 26
gauge needle. Subcutaneous and metastatic tumor
growth and incidence were monitored using BLI (see
below). Immediately after intracardiac injection of
LeoYFP-Luc cells, a diffuse BLI signal originating from
the tumor cells throughout the entire body was con-
sidered successful left ventricular injection. Mice were
sacrificed after 4 weeks.
Bioluminescent imaging
Mouse BLI was performed using an in vivo imaging
system (IVIS 100, Caliper Life Sciences, Hopkinton,
MA) as described previously [11]. Briefly, 4.5 mg d-
luciferin (Caliper Life Sciences) dissolved in 150 ml PBS
was injected intraperitoneally into mice and imaging
was carried out in an imaging chamber under general
anesthesia with a 1.5% isoflurane – oxygen mixture
until peak photon signal was attained. The photon
signal intensitywas quantified using LivingImage soft-
ware version 2.50 (Caliper Life Sciences).
Invitrogrowthrate
Cells (5  105) frompassage 70were plated in 10 cm
plates (Falcon) in quadruplicate in DMEM/F12
medium with 10% FBS and 50 mg/ml Normocin
(Invivogen) and incubated at 378C in 5%CO2. The cells
were harvested using 0.25% trypsin (Fisher Scientific,
Pittsburgh, PA) at 24, 48, and 72 hr after plating and
counted with an automated cell counter (Nexcelom
Bioscience, Lawrence, MA) using trypan-blue dye
exclusion to count live and dead cells. Doubling time
was calculated using the formula: (t2  t1)  log(n2)/
log(n2/n1), where n is the cell number at time points (t)
[14].
Radiographyofmice
High-resolution radiographic images of mice were
obtained using a Faxitron laboratory radiography
system LX-60 (Faxitron X-ray Corp., Wheeling, IL) at
30 KVp for 10 sec on day 28.
Histopathologyandimmunohistochemistry
Complete necropsies were performed on the mice
and tissues were fixed in 10% neutral-buffered for-
malin at 48C for 24 hr. Bones were decalcified in 10%
EDTA (pH 7.4) for 2 weeks at 48C and embedded in
paraffin. The specimens were sectioned (5 mm) and
were either stained with hematoxylin and eosin
(H&E) or evaluated by immunohistochemistry using
human antibodies for the presence of cytokeratin (CK)-
5/14, 8, 18, 7, vimentin, androgen receptor (AR) and
prostate specific antigen (PSA) to characterize the pros-
tate carcinoma cells (see Table I for a list of primary
antibodies). Sections were deparaffinized in xylene
(Hemo-De, Fisher Scientific, Bay Shore, NY) by two
3-min washes and rehydrated in 100%, 95%, and
70% ethanol sequentially for 3 min and rinsed inwater.
Endogenous peroxidase activity was removed using
3% H2O2 (Dako Corp., Carpinteria, CA) for 5 min at
room temperature (RT) and washed in PBS for 15 min.
Toblock non-specific binding of proteins, sectionswere
incubated in Protein Block (Dako Corp.) for 15 min at
RT and rinsed in PBS. Antigen retrieval was performed
using target retrieval solution and heated for 30 min in
an oven at 608C. Primary antibodies (see Table I) were
added to sections and incubated at RT for 30 min and
sections were washed three times for 5 min in PBS/
0.05% Tween. After washing, sections were incubated
either with universal biotinylated goat anti-mouse or
TABLE I. Anti-HumanAntibodiesUsed for Immunohistochemistryof the Primary Prostate Carcinoma
Antibody Species Clone Company Dilution
MA903 (CK5/14) Mouse 34bE12 Enzo Life Sciences, Farmingdale, NY 1:100
CK18 Mouse KS-B17.2 Sigma–Aldrich, St Louis, MO 1:100
CK8 Mouse 4.1.18 Chemicon, Temecula, CA 1:30
Vimentin Mouse Clone V9 Cell Marque, Hot Springs, AR 1:50
CK7 Mouse OV-TL12/30 Dako Corporation, Carpinteria, CA 1:40
AR Rabbit N-20 Santa Cruz Biotechnology, Inc, Santa Cruz, CA 1:500
PSA Rabbit Polyclonal Dako Corporation, Carpenteria, CA 1:150
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biotinylated goat anti-rabbit IgG secondary antibody
(1:250 dilution in protein block reagent) for 30 min at
RT and followed by three 5-min washes in PBS/0.05%
Tween. Sections were incubated with avidin–biotin
complex for 30 min according to the manufacturer’s
instructions (Vectastain ABC Kit, Vector Laboratories,
Inc., Burlingame, CA). To visualize the peroxidase
activity, sectionswere incubatedwith 3,30-diaminoben-
zidine reagent (1:50 concentrate:reaction buffer) for
5 min at RT and rinsed in distilled water. The slides
were counterstained with hematoxylin for 1 min,




Total RNA was extracted from Leo cells, Ace-1 dog
prostate cancer cells [4], dog transitional cell carcinoma
(TCC) cells [15] and dog brain using Trizol reagent
according to manufacturer’s protocol (Invitrogen).
Total RNA (2.5 mg) was reverse transcribed using
the Superscript II First Strand cDNAsynthesis kit (Invi-
trogen) and RT-PCR was performed for parathyroid
hormone-related protein (PTHrP), matrix metallopro-
teinase (MMP-9), vascular endothelial growth factor
(VEGF), beta2-microglubulin (B2M), receptor activator
of NF-kappaB ligand (RANKL), osteoprotegerin
(OPG), nerve growth factor (NGF), low-affinity nerve
growth factor receptor (LNGFR), and neurotrophin
tyrosine receptor kinase 1 (NTRK1) using canine-
specific primers (Table II).
PTHrPimmunoradiometric assay
PTHrP concentrations were measured in the Leo
cell conditioned medium at 0, 6 12, 24 hr after the
addition of serum-containing medium. Negative con-
trol medium was not conditioned by any cells. PTHrP
concentration was quantified using a two-site im-
munoradiometric assay (DSL, Webster, TX) specific
for PTHrP 1-80 using antibodies to the N-terminal
region (amino acids 1–40) andmid-region (amino acids
57–80) according to manufacturer’s instructions.
Analysisof Leogenomicimbalancesby fluorescent in
situhybridization (FISH)
Cellswere grown to80% confluence and 50 ng/ml
of Karyomax (Invitrogen) were added to the medium
and incubated at 378C for 4 hr. Chromosome prep-
arations were generated following conventional pro-
cedures of hypotonic treatment and fixation in 3:1
methanol:glacial acetic acid. Chromosome prep-
arations were counterstained with 80 ng/ml 40,6-dia-
minidino-2-phenylindole (DAPI) and mounted in
antifade solution (Vectashield, Vector Laboratories).
Images were acquired with a fluorescence microscope
(Axioplan 2ie, Zeiss) equipped with a DAPI filter set
and a cooled CCD camera (CoolSnapHQ, Photo-
metrics, Tuscon, AZ) both driven by dedicated soft-
ware (SmartCapture 3, Digital Scientific, Cambridge,
UK). Thedigital imageof eachDAPI stainedmetaphase
spreadwas processed using a high-pass spatial filter to
reveal enhanced DAPI bands [16,17]. Chromosome
counts were obtained from 50metaphase preparations.
To identify the position of the centromeres of the
chromosomes, two BAC clones (330E21 and 326K03)
from the CHORI-82 BAC library, which have been
TABLE II. Dog-Specific PrimersUsed for RT-PCRAmplification










TABLE III. Incidenceof LeoYFP-LucMetastasesbyAnatomic
Location at 28 days Following Intracardiac Injection
Site of metastasis Incidence







shown previously to hybridize to all autosomal cen-
tromeres of the canine genome [18], were labeled with
SpectrumGreen-dUTP and hybridized to chromosome
preparations of this cell line according to routine pro-
cedures [19].
Caninegenome2.0 arrays
RNAwas extracted from Leo cells and purifiedwith
Absolutely RNA1 Miniprep Kit (Stratagene, La Jolla,
CA). RNA was assayed for quality using Agilent RNA
6000 Nano Assay (Santa Clara, CA). Only samples
exhibiting minimal degradation as evidenced by
RNA integrity numbers>8 were used for mircoarrays.
Three samples at three separate passages were selected
and array analysis with GeneChip Canine 2.0 Genome
Arrays (Affymetrix, Santa Clara, CA)was performed at
OSU’s Comprehensive Cancer Center Microarray
Shared Resource. Background correction and normal-
izationwasperformed to avoid technical bias, andgene
expression level was summarized over the probeset
using the RMA method. A Linear model was per-
formed to detect differentially expressed genes [20].
In order to improve the estimates of variability and
statistical tests for differential expression, variance
shrinkage method was employed for this study [21].
The significance level was adjusted by controlling the
mean number of false positives [22].
Data analysis
The half maximum inhibitory concentrations (IC50)




In the dog, the normal prostate gland was replaced
by a highly invasive carcinoma consisting of multiple
lobules of polygonal to columnar cells arranged in large
sheets of cells and nests of cells separated by dense
fibrous connective tissue (typical of the alveolar pattern
of canine prostate cancer). Neoplastic cells had abun-
dant cytoplasm with occasional cells containing a
single, round, clear cytoplasmic vacuole, which dis-
placed the nucleus (signet ring formation). Binucleate
cells were often apparent and up to three nucleoli were
present in the nuclei (Fig. 1A). Neoplastic tissue had
regions of necrosis with secondary inflammation. The
carcinoma invaded into the trigone region of urinary
bladder andmetastasized to the iliac lymphnode, liver,
lung, and right proximal tibia. The central nervous
system was not examined since the dog had no neuro-
logic clinical signs.
Fig. 1. Photomicrographsofprimaryprostatecarcinoma, invitro
cell line (Leo) and subcutaneous xenograft. A: Photomicrograph
of H&E-stained primary prostate carcinoma.Note the solid carci-
noma consisting of multiple lobules of polygonal to columnar cells
(alveolar pattern) separated by fibrous connective tissue. Bar,
50 mm. B: Phase contrast microscopy of Leo cells (passage 65).
The polyhedral cells have a tightly packed cobblestone growth pat-
tern. Bar, 20 mm. C: Photomicrograph of H&E-stained subcu-
taneous Leo xenograft. Tumors were multilobular with large
polygonal cells.Bar, 50 mm.
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Developmentof Leoprostate cancercell Line
The prostate cancer cell line, Leo, was established
from the primary prostate carcinoma tissue. The cell
line has been passaged over 75 times in vitro. The cells
grow in an anchorage-dependentmanner inmonolayer
sheets with polyhedral cells exhibiting a tightly packed
cobblestone growth pattern (Fig. 1B).
SubcutaneousgrowthofLeoprostatecarcinomacells
Leo cells injected into the subcutaneous region of
nude mice formed tumors that average 0.8 cm3 in
6 weeks (Fig. 4C). The microscopic appearance of the
Leo subcutaneous xenografts was similar to the
primary carcinoma. (Fig. 1C).
Immunohistochemistryoftheprimary
prostate carcinoma
The primary prostate carcinoma was moderately
positive for CK8 (Fig. 2A) and strongly expressed
CK18 (Fig. 2B),which aremarkers of prostatic secretory
cells. The cancer cells were negative for basal cell CK
markers CK5 and 14 (data not shown). Previously it
was reported that prostate cancer can originate from
ductal cells in dogs and express the CK marker, CK7
[23,24]. The primary cancer cells expressed CK7 stain-
ing in the cytoplasm (Fig. 2C). AR, human PSA, and
vimentin were not expressed by the carcinoma cells
(Data not shown). Dog prostate glands do not express
human PSA, but have a related kallikrein, arginine
esterase (AE) [25]. The canine genomic array demon-
strated that the Leo cells expressedAEat three different
passages (passage 12, 13, and 14).
RT-PCRandPTHrPsecretionof
theLeoprostate cancercellline
Leo cells expressed mRNA for MMP-9 and VEGF
(Fig. 3), which have been reported to play an important
role in the development of brain metastases [26,27].
RANKL and OPG were expressed by the Leo cells
(Fig. 3) and might play a role in the bone metastases
developed by Leo cells after intracardiac injection.
Expression of PTHrP, NGF, LNGFR, and NTRK1 were
not detectable. PTHrP concentrations in Leo cell con-
ditioned media at different time points were similar to
control medium without cells.
Invitrogrowthandinvivotumorigenicity
Leo cells grew exponentially in vitrowith adoubling
time of approximately 38 hr under standard cell cul-
ture conditions (Fig. 4A). Leo cells were transduced
with YFP-Luc to monitor in vivo growth. The LeoYFP-
Luc cells were injected into the subcutis of nude mice to
test their tumorigenicity. Subcutaneous tumor growth
was detected in all mice (n ¼ 10) and was progressive
over 6 weeks (Fig. 4B and C).
Metastasesof Leocells innudemice
Left ventricular intracardiac injections of LeoYFP-Luc
were performed in 25 male nude mice in two separate
Fig. 2. Immunohistochemistry of the primary prostate carci-
noma.A: CK8 staining in the cytoplasmwasmoderately positive.
B: CK18 staining in the cytoplasm was strongly positive.C: CK7
staining in cytoplasmwasmoderatelypositive.Bars, 20 mm.
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experiments. Metastatic ability of tumor cells was
monitored weekly using BLI. At day 7, BLI signal
wasundetectable indicating thatmost injectedLeo cells
died. On day 14,metastatic foci were detected by BLI at
different sites including the head, hind limbs, vertebrae
and scapular region. BLI intensity of themetastatic foci
increased at days 21 and 28. Metastases were detected
in 23/25 mice. Mice were sacrificed on day 28 and
ex vivo imaging of individual organs were performed
immediately to localize the metastases. Metastases
detected by BLI were confirmed by histopathological
evaluation.
Histopathological analysis showed the presence of
prostate carcinoma in the brain (19/25 mice), spinal
cord (2/25 mice), adrenal gland (4/25), long bones (5/
25), and scapula (1/25) (Table III). Leo cells most com-
monly metastasized to brain (Fig. 5A and B) when
compared to other organs. Tumors in the brain ranged
from 1 mm to 5 mm in diameter and multiple meta-
static foci were observed in each brain section. Meta-
static tumor in the brain and spinal cord (Fig. 5C andD)
was most frequently located within the white matter.
The brain and spinal cord metastases were expansile
with compression of surrounding neurophil consistent
with tumor size.Central necrosis andhemorrhagewere
features of larger tumors within the brain. Adrenal
metastases replaced the medulla and cortex of the
adrenal gland (Fig. 5E and F). In long bone metastases,
such as tibia and femur, tumor cells caused osteolysis
characterized by loss of cortical and trabecular bone in
the metaphyseal region (Fig. 6A–C). The single
metastatic lesion to the scapula was osteoblastic and
consisted of tumor cells surrounding the scapular bone
and containing large radiating bands (50 mm wide) of
new woven bone proliferation lined by tall cuboidal
osteoblasts (Fig. 6D–F).
Invitro chemosensitivity
The in vitro chemosensitivity of the Leo cells to
different doses of calcitriol, piroxicam, (S)-HDAC-42
Fig. 3. mRNA expression of Leo cells. Expression of MMP-9,
VEGF,OPG,RANKLmRNAwere detectedusingRT-PCRincanine
prostate cancer cells lines; Ace-1 and Leo and a dogTCC cell line.
Expression ofb2microglobulinwas used as a control.
Fig. 4. Invitro andinvivogrowthpatternsofLeo cells.A: Invitro
growthcurveofLeocells.Datapresentedasmean þ standarddevi-
ation of four replicates.B: Graph represents the average intensity
of the BLI signal measured at the indicated time points.C: Graph




(Ar-42) and Velcade (bortezomib) wasmeasured using
the MTT assay at 72 hr. All the drugs inhibited cell
growth in a dose-dependent manner. The half maxi-
mum inhibitory concentrations (IC50) were calculated
using Calcusyn software andwere 6.5 mM for calcitriol
(Fig. 7A), 1.9 nm for Velcade (Fig. 7B), 0.95 mm for (S)-
HDAC-42 (Fig. 7C) and 518 mmfor piroxicam (Fig. 7D).
The in vitro IC50 concentrations of calcitriol and pirox-
icam were higher than what is accepted as physiologi-
cally achievable in patients. Leo cells were most
sensitive to (S)-HDAC-42 and Velcade compared to
calcitriol and piroxicam.
GenomicimbalancesinLeo cells
All of the 50 cells evaluated for chromosomenumber
were hyperdiploid, containing between 120 and 138
chromosomes, with a mean of 131. Seventy-five per-
cent of the cells had a count between 130 and 135.
Typical metaphase spreads of Leo cells (Fig. 8Ai,ii)
showed that most of the chromosomes were short
armed and 6–8 chromosomes were bi-armed. Centro-
meres were not detected in three chromosomes using
BAC clones thatwere previously shown to hybridize to
all canine autosomes, suggesting that these three aber-
rant chromosomes may contain centromeres from the
sex chromosomes (Fig. 8Bi, ii) [18].
DISCUSSION
Understanding the pathogenesis of prostate cancer
and development of novel therapeutic agents can be
improved with additional unique cell lines and in vivo
animal models that mimic the condition in men [7].
Therefore, development of new cell lines and animal
models that closely recapitulate the clinical disease in
patients are crucial to understand themolecular hetero-
geneity and pathogenesis of prostate cancer. Dogs not
Fig. 5. Invivo BLI andhistopathologic evaluation of nudemice 28 days following intracardiac injection of LeoYFP-Luc cells (A)wasperformed
in ventral (a) and lateral (b,c) recumbency and demonstratedmetastasis to the cranium.B: H&E-stained coronal section of brain revealed a
largemetastatic carcinoma (T, right side) with multiple small metastases in the brain parenchyma.BLI evaluation of spinal cordmetastasis.
Bar, 500 mm (C).Histopathologic evaluation (D) showed a metastatic carcinoma (T) in thewhitematter of spinal cord (H&E).Bar,100 mm.
BLI evaluation revealed a metastasis to the lumbar region (E), whichwasmicroscopically confirmed as an adrenalmetastasis.Bars, 250 mm
(F).Tumor cells are indicatedby (T), adrenal cortexby (CT) and adrenalmedulla by (M),H&E.
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only develop spontaneous prostate cancer but also
share similarities to the clinical presentation of prostate
cancer in men [2,11,28]. In the present study, we
described the establishment of a novel dog prostate
cancer cell line (Leo) and characterization of its tumor-
genicity and metastatic ability to various organs in
nude mice.
The Leo cell line was developed from a 5-year-old
castrated male mixed breed dog. The Leo cells formed
tumors in the subcutis of nude mice demonstrating its
tumorgenicity in vivo. Following intracardiac inocu-
lation, the Leo cells metastasized to multiple sites
including the brain, spinal cord, bones, and adrenal
gland. TheLeoprostate cancer cells exhibited a remark-
able tropism for developing metastases in the brain
based on the 80% incidence of brain metastases. It
has been reported that MMP-9 is up-regulated in most
brain metastases [26]. MMP-9 belongs to matrix metal-
loprotease family of enzymes that degrades the extra-
cellular matrix leading to invasion of tumor cells [29].
High expression of MMP-9 by Leo cells suggests that it
might play a significant role in the development
of brain metastases. Increased VEGF expression by
cancer cells helps in angiogenesis and transendothelial
migration by regulating the permeability of brain
microvascular endothelial cells [30]. The Leo cells
express VEGF,whichmay be important in the develop-
ment of brain metastases seen in this model. Although
VEGFandMMP-9may facilitate brainmetastasis, other
factors must also be involved because the Ace-1 and
TCC cell lines also produce VEGF and MMP-9 and do
not metastasize to the brain.
Fig. 6. Evaluation ofbonemetastasis on day 28 following intracardiac injection of LeoYFP-Luc in nudemice.A:BLI showedmetastasis to the
left hind limb.B:Radiographic evaluation showedosteolysis (arrow) in themetaphyseal region of thehumerus.C:Histopathologic evaluation
showed that tumor (T) replacedbonemarrow in themetaphysis and diaphysis of humerus.Themetastasis caused extensive bone osteolysis





The brain is a rich source ofNGF,which is important
in the development andmaintenance of nervous tissue
[31]. NGF regulates its action by binding and activating
to two types of neurotrophin receptors, a low affinity
nerve growth factor receptor (LNGFR or P75) and
NTRK [32]. However, expression of NGF, LNGFR,
and NTRK1 were not detectable in Leo cells. Leo cells
had severe chromosomal imbalances such as hyper-
diploidy and bi-armed chromosomes. Further evalu-
ation of the chromosome imbalances will be important
to understand the molecular pathogenesis of metasta-
sis of the Leo cells.
Dog prostate cancers can have mixed histologic fea-
tures of adenocarcinoma and ductal differentiation [2].
It has been suggested that prostate cancer in dogs may
originate from prostate ductal cells that are positive for
CK7 [23,24]. Expression of CK7 in addition to secretory
epithelial CKs, 8, and 18, by the Leo cells suggests that
they have differentiated towards both secretory and
ductal cells. Ductal cells with CK7 expression in dogs
may also have urothelial differentiation [24].
The AR in dogs is expressed in prostate secretory
and basal epithelial cells, ductal cells, stromal cells, and
the prostatic urethra [23]. However, in neutered dogs
theAR is not expressed. Lack of expression ofAR in the
Leo cell line, developed from a prostate carcinoma in a
neutered dog, is consistent with previous reports
and typical of an androgen-insensitive canine prostate
carcinoma [23]. The Leo cells were negative for vimen-
tin, which is generally expressed by stromal cells
although it has been reported in some prostate cancer
cells suggesting epithelial to mesenchymal transition
[4]. PSA, a biomarker of prostate cancer in human, is
expressed in glandular epithelium and liquefies the
semen by degrading semenogelin [33,34]. PSA belongs
to the family of kallikrein genes and it is encoded by
kallikrein 3. In human 15 kallikreins were identified
whereas in dogs only 14 kallikreins are present. The
human kallikrein 3 gene encoding PSA in humans is
absent in dogs [35]. However, dog kallikrein 2, encod-
ing AE, shares 58% amino acid homology with human
PSAandboth genes are regulated by androgens [36,37].
Polyclonal and monoclonal PSA antibodies cross-react
with human kallikreins 1 and 2 since the degree of
amino acid homology is 80% [38]. A few reports have
demonstrated staining for PSA (using antibodies to
human PSA) in normal dog prostate and canine pros-
tate cancers [39]. Presumably this may be due to cross-
reactivity to canine AE. However, since dogs lack a
homolog to human PSA, PSA assay and immunohis-
tochemistry generally are not useful in dogs [39]. The
Leo cells did express AE.
The bone metastases that developed in nude mice
with the Leo cells were predominantly osteolytic
Fig. 7. Dose-responseofLeocellviability tocalcitriol (A),Velcade(B), (S)-HDAC-42(Ar-42)(C)andpiroxicam(D) treatment.AnMTTassay
was performed with six replicates for each dose for 72 hr. IC50 values for calcitriol, piroxicam, (S)-HDAC-42 and Velcade were 6.8 mm,
518 mm,0.95 mm, and1.9 nm, respectively.Bars representmean þ standarddeviation of six replicates.
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similar to that observed in the dog with the tibial meta-
stasis. Dog prostate cancer metastases to bones mostly
affect the axial skeleton and proximal long bones and
can be osteoblastic, osteolytic, or mixed [2]. We have
also developed a nude mouse model of dog prostate
cancer using the Ace-1 cells that develop a 100% inci-
dence of mixed osteoblastic and osteolytic bone meta-
stases [11]. The Leo cells have a unique metastatic
pattern in vivo with a relatively low incidence of meta-
stases to bone (20%). The RANKL and OPG axis has
been shown to play an important role in regulating
osteolytic bone metastases [40]. RANKL expressed
by prostate cancer cells binds to RANK receptor
expressed on the surface of osteoclast precursors and
induces their differentiation andmaturation into active
osteoclasts. OPGexpressedby cancer cells acts as decoy
receptor for RANKL and prevents it from binding to
RANKresulting in inhibition of osteoclastogenesis [41].
Leo cells, similar to the Ace-1 prostate cancer cell line,
express high levels of both RANKL and OPG. The
RANKL may be responsible for the induction of osteo-
clastic bone resorption, and the amount of OPG is not
adequate to inhibit the osteoclastic bone resorption in
the metastases. The Leo cells likely do not make sig-
nificant osteoblastic factors that are a characteristic of
the Ace-1 cells.
Velcade (bortezomib), a proteosome inhibitor, was
shown to inhibit prostate cancer growth and osteolytic
bone metastases in pre-clinical models [42]. Leo cells
were very sensitive to Velcade with an IC50 of 1.9 nm.
Serum concentrations of Velcade in human patients
of 40 to 90 ng/L were shown to have anti-tumor
activity without serious adverse effects [43,44]. There-
fore, it will be important to test the efficacy of Velcade
on tumor growth and metastases in the Leo model
of prostate cancer. A novel HDAC-42 (Ar-42) inhibitor
developed at Ohio State University was very effective
in inhibiting the growth of Leo cells in vitro with an
IC50 of 0.95 mm at after 72 hr of treatment. This
novel phenylbutyrate-derived HDAC inhibitor was
shown to possess potent anti-tumor activity in
prostate cancer by inducing apoptosis [45]. Despite
the fact that calcitriol and piroxicam had inhibited
the Leo cell growth, the IC50 concentrations were too
great to achieve relevant serum levels in clinical
patients.
Fig. 8. Ai,ii:TypicalmetaphasechromosomepreparationsderivedfromLeocells,exhibitingchromosomenumbersinexcessof130percell.In
addition to the high number of chromosome number, there are several bi-armed chromosomes indicative of structural as well as numerical
changes.Bi: Hybridization of two BAC clones thatmap to all autosomes of the canine genome revealed that centromereswere detected in
allbutnine chromosomes (arrows).Bii: Overexposure of the samemetaphase spreadswasunable to detecteven aweak signal at the centro-
meres of three (red, yellow andwhite arrowheads) of thenine chromosomes.
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One of the most important findings of the Leo xen-
ograftswas the consistent and frequent development of
brain metastases in nude mice. To our knowledge, this
is the first prostate cancer cell line that consistently
develops brain metastases in vivo. This provides a
unique translationalmodel to investigate thepathogen-
esis of brainmetastases anddevelop potent therapeutic
strategies to treat or prevent brain metastases. Though
the incidence of bone metastases was not high, it may
be feasible to develop a subline of the Leo cells with
a high rate of bone metastases, which would be a
valuable model to study the skeletal complications of
prostate cancer. Therefore, the new Leo prostate cancer
cell line provides a valuable tool to help understand the
molecular mechanisms responsible for the pathogen-
esis of prostate cancer and metastases to the brain and
bone.
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